As reported by Law360 (subscription), Allergan has agreed to pay $30 million to settle an antitrust lawsuit filed by Lieff Cabraser and co-counsel on behalf of a group of pharmaceutical purchasers, union benefit plans, and other buyers of Allergan’s blockbuster dry-eye disease drug Restasis. The sweeping litigation accused the drugmaker of
If You Bought or Provided Reimbursement for the Dry-Eye Disease Drug Restasis® You Could Be Included in a Class Action Lawsuit For more detailed information, visit: www.RestasisLitigation.com Para conseguir una notificación en español, llame a 1-877-868-6810 o visite el sitio web: www.RestasisLitigation.com.
As reported by Law360 (subscription), a New York federal judge has granted class certification in an antitrust lawsuit wherein Lieff Cabraser and co-counsel represent a group of pharmaceutical purchasers, union benefit plans, and other buyers of Allergan’s blockbuster dry-eye disease drug Restasis. The sweeping litigation accuses the drugmaker of misconduct intended
As reported in Law360 (subscription), plaintiffs in the multidistrict litigation against pharmaceutical manufacturer Allergan have successfully defeated a motion to dismiss the case alleging antitrust violations with respect to the sale and marketing of dry-eye drug Restasis. The Court’s ruling favored a group of pharmaceutical purchasers and union benefit plans accusing